ARTICLE | Company News
AmVac, National Health Research Institutes deal
December 22, 2008 8:00 AM UTC
The partners will use AmVac's MALP-2 synthetic lipopeptide vaccine adjuvant to develop an intranasal avian influenza vaccine, to which they will share rights. Phase I trials are planned for 2011. Furt...